Recent Quotes
My Watchlist
Indicators
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

8.310 -0.110 (-1.31%)
Delayed Quote Updated: 2:19 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Contineum Therapeutics, Inc. - Common stock

< Previous 1 2 3 Next >
Monday's session: top gainers and losers ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
Contineum Therapeutics (NASDAQ:CTNM) Reports Q4 2025 Loss, Highlights Clinical Progress and Extended Cash Runway ↗
Via Chartmill
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
News headline image
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential ↗
Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent... 
Via MarketBeat
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
From Contineum Therapeutics
Via Business Wire
News headline image
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
From Contineum Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>